SOPHiA GENETICS And AstraZeneca Collaborate To Further Expand Global Access To Liquid Biopsy Testing; SOPHiA GENETICS Will Accelerate The Deployment Of MSK-ACCESS Powered With SOPHiA DDM To 20 Locations Worldwide Over The Next 12 Months
Portfolio Pulse from Benzinga Newsdesk
SOPHiA GENETICS and AstraZeneca have partnered to expand global access to liquid biopsy testing. They plan to deploy the MSK-ACCESS test, powered by SOPHiA DDM, to 20 locations worldwide over the next 12 months.
September 10, 2024 | 2:18 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
AstraZeneca collaborates with SOPHiA GENETICS to expand access to liquid biopsy testing, deploying MSK-ACCESS to 20 locations globally over the next year.
The collaboration with SOPHiA GENETICS to expand liquid biopsy testing aligns with AstraZeneca's strategic focus on innovative healthcare solutions, potentially enhancing its market position.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 70
POSITIVE IMPACT
SOPHiA GENETICS is set to expand its liquid biopsy testing globally through a partnership with AstraZeneca, deploying MSK-ACCESS to 20 locations in the next year.
The partnership with AstraZeneca and the planned global deployment of MSK-ACCESS could enhance SOPHiA GENETICS' market presence and revenue potential, likely boosting investor sentiment.
CONFIDENCE 95
IMPORTANCE 85
RELEVANCE 90